|Day Low/High||66.81 / 69.78|
|52 Wk Low/High||60.89 / 71.19|
Company has an agreement with Chinese authorities to study the effectiveness of an experimental Ebola and SARS treatment on coronavirus patients.
Gilead offers a nearly 4% yield and looks ready to return to growth.
RBC analysts expect Alibaba and Salesforce to continue posting strong double-digit sales growth, and remain fans of Constellation's M&A-driven growth strategy.
Biotech is on fire right now, but these 3 stocks 'sleeper' stocks aren't yet overbought.
The planned acquisition of The Medicines Company by Novartis spurs prospects of other deals in the drug business.
"Politics: "Poli" a Latin word meaning "many" and "tics" meaning "bloodsucking creatures" - Robin Williams Markets are looking good a half hour into the trading day. All the major indices are nicely in the black with the NASDAQ up approximately one ...
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.
Use buy-write orders as a conservative way to invest in GILD in these uneasy times.
Let's see if either of these names provide an entry this week.
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
Revenue is stabilizing with new treatment lines, and this stock may be a soon be a buy.
Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.
Market is pretty much where it has been all day, nicely positive across the board. Biotech up nearly 2% on the day. Gilead Sciences, Inc. , and Celgene Corp. , are two large caps on the move for reasons we covered in previous posts. The Bristol-Myer...
The market has given up some of its early gains, but the major indices are all still in the black. Homebuilders have given up their 1% rally early today and now are flat. The Atlanta Fed's GDPNow has the economy growing 1.7% now from the last readin...
Less than a hour to go before the market open as we await the last trading day of the first quarter. Pre-market futures are still pointing to a up opening. Gilead Sciences is up some 2% this morning after developmental partner Galapagos announced so...
The RMPIA rose 10.5% during the first half of the current quarter.
I still believe it will be a big year for buyouts across the biotech industry.
It's behavioral finance at its finest, and makes for a fascinating debate.